IQVIA Holdings Inc. (NYSE:IQV) Director Purchases $255,739.50 in Stock

IQVIA Holdings Inc. (NYSE:IQV) Director John G. Danhakl bought 1,275 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

IQVIA Stock Down 0.9 %

IQV stock traded down $1.83 during midday trading on Friday, hitting $208.13. The stock had a trading volume of 1,748,692 shares, compared to its average volume of 1,441,224. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market cap of $37.78 billion, a price-to-earnings ratio of 27.31, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. The business has a 50-day moving average of $200.53 and a two-hundred day moving average of $219.80. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on IQV shares. Redburn Atlantic began coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. TD Cowen lowered their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Finally, Bank of America lowered their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $252.39.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently modified their holdings of IQV. Raymond James Financial Inc. purchased a new stake in IQVIA during the 4th quarter valued at about $236,120,000. FMR LLC lifted its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA during the third quarter valued at approximately $147,683,000. JPMorgan Chase & Co. raised its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.